No Record Found
No Record Found
Sector
PharmaceuticalsOpen
₹644.9Prev. Close
₹672.4Turnover(Lac.)
₹153.48Day's High
₹684Day's Low
₹622.152 Week's High
₹839.9552 Week's Low
₹277.95Book Value
₹482.79Face Value
₹10Mkt Cap (₹ Cr.)
902.67P/E
12.31EPS
52.85Divi. Yield
08 Jul 2025
12:00 AM
AGM
Announcement Date: 08 Jul, 2025
8 Jul 2025
12:00 AM
BookCloser
19 Jan 2026
12:00 AM
Board Meeting
Agenda : Audited Result
The Unit-II Baddi plant, which got the renewed certification, has state-of-art infrastructure and state-of-the-art manufacturing technology to cater to complex therapeutic segments in an efficient manner.
The company is now set to further expand into Eastern Europe as this recognition ensures patients and healthcare providers have access to reliable and effective antibiotics.
Furthermore, the NPRA's recognition will enable Venus Remedies to capitalise on the expanding global demand for enoxaparin.
| Y/e 31 Mar( In .Cr) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 |
|---|---|---|---|---|
Equity Capital | 13.37 | 13.37 | 13.37 | 13.37 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 576.13 | 495.22 | 464.68 | 436.05 |
Net Worth | 589.5 | 508.59 | 478.05 | 449.42 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 575.18 | 514.62 | 322.35 | 355.07 |
yoy growth (%) | 11.76 | 59.64 | -9.21 | -5.42 |
Raw materials | -375.96 | -336.68 | -176.8 | -205.42 |
As % of sales | 65.36 | 65.42 | 54.84 | 57.85 |
Employee costs | -43.74 | -35.88 | -33.78 | -27.82 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 44.67 | 17.61 | 2.54 | -23.42 |
Depreciation | -32.57 | -34.28 | -31.05 | -32.72 |
Tax paid | 4.31 | 13.21 | -1.96 | -3.16 |
Working capital | 55.88 | -86.12 | 20.69 | -11.18 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 11.76 | 59.64 | -9.21 | -5.42 |
Op profit growth | 46.85 | 8.81 | -1.13 | -7.88 |
EBIT growth | 47.2 | 94.58 | 34.96 | 31.88 |
Net profit growth | -9.73 | -759.69 | -69.05 | 31.32 |
| Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|---|
Gross Sales | 652.89 | 601.45 | 555.51 | 600.18 | 548.12 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 652.89 | 601.45 | 555.51 | 600.18 | 548.12 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 25.86 | 11.58 | 10.32 | 8.31 | 43.07 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,750.5 | 96.36 | 4,20,531.44 | 705.44 | 0.91 | 5,651.21 | 99.24 |
Divis Laboratories Ltd DIVISLAB | 6,316 | 66.08 | 1,69,988.82 | 598 | 0.47 | 2,578 | 578.26 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 4,341 | 66.24 | 1,47,936.19 | 577 | 0.14 | 2,547 | 249.82 |
Cipla Ltd CIPLA | 1,313.2 | 23.83 | 1,09,199.83 | 616.88 | 1.18 | 4,256.93 | 411.55 |
Dr Reddys Laboratories Ltd DRREDDY | 1,291.2 | 23.29 | 1,08,057.06 | 90.6 | 0.62 | 4,266.4 | 377.55 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman / WTD / Managing Director / CFO
Pawan Chaudhary
Whole Time Director & JMD
Manu Chaudhary
Whole Time Director / Deputy Managing Director
Peeyush Jain
E D & Wholetime Director
Ashutosh Jain
Whole Time Director & CTO
Akshansh Chaudhary
Independent Director
Navdeep Sud
Independent Director
Savita Gupta
Independent Non Exe. Director
Navdeep Sud
Independent Non Exe. Director
Pravindra Singh Chauhan
Independent Non Exe. Director
Nps Monga
Independent Non Exe. Director
Anil Kumar
Independent Non Exe. Director
Jagdish Chander Sharma
Company Sec. & Compli. Officer
Neha Arora
S C No 857 Cabin No 10 2nd Flr,
N A C Manimajra,
Chandigarh - 160101
Tel: -
Website: http://www.venusremedies.com
Email: investorgrievance@venusremedies.com; complianceoff
Narang Tower,
44 Community Centre, Naraina Ind Area,
New Delhi-110028
Tel: 91-11-41410592-94
Website: www.linkintime.co.in
Email: delhi@linkintime.co.in
Summary
Incorporated in 1989 Venus Remedies Limited, formerly known as Venus Glucose Pvt Ltd, was converted into Public Limited Company in 1994 and then changed into Venus Remedies Limited. The Company was pr...
Read More
Reports by Venus Remedies Ltd
What is the Venus Remedies Ltd share price today?
What is the Market Cap of Venus Remedies Ltd?
What is the PE and PB ratio of Venus Remedies Ltd?
What is the 52 Week High and Low of Venus Remedies Ltd?
What is the CAGR of Venus Remedies Ltd?
What is the shareholding pattern of Venus Remedies Ltd?
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
